找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Dyslipidemias in Kidney Disease; Adrian Covic,Mehmet Kanbay,Edgar V. Lerma Book 2014 Springer Science+Business Media New York 2014 Dialysi

[復(fù)制鏈接]
樓主: Extraneous
11#
發(fā)表于 2025-3-23 11:07:44 | 只看該作者
Book 2014e latest clinical evidence and management guidance for patients of various demographics and stages of chronic kidney disease. Written for the nephrologist community, as well as cardiologists and general practitioners, this guide will provide practical knowledge and fill a much needed void in the literature..
12#
發(fā)表于 2025-3-23 17:10:12 | 只看該作者
Environmental Resources Limitedn hemodialysis and peritoneal dialysis patients, and even in kidney transplant recipients. These abnormalities contribute to the risk of cardiovascular disease in these patients. Moreover, dyslipidemia may adversely affect the progression of renal disease in patients with CKD.
13#
發(fā)表于 2025-3-23 20:15:35 | 只看該作者
14#
發(fā)表于 2025-3-24 00:57:51 | 只看該作者
Hans Wu?ing,D. Goetz,I. Jahn,Hans Wu?ingrecommended. Pharmacological intervention with statin therapy is recommended based on results from the ALERT study, although there is a reluctance to prescribe these agents in transplant recipients due to risk of side effects and drug interactions.
15#
發(fā)表于 2025-3-24 06:09:20 | 只看該作者
Epidemiology/Prevalence of Dyslipidemia in the General Population and in Patients with Chronic Kidnn hemodialysis and peritoneal dialysis patients, and even in kidney transplant recipients. These abnormalities contribute to the risk of cardiovascular disease in these patients. Moreover, dyslipidemia may adversely affect the progression of renal disease in patients with CKD.
16#
發(fā)表于 2025-3-24 07:08:07 | 只看該作者
Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease,chapter is to discuss the pharmacokinetic and pharmacodynamic properties of lipid-lowering drugs in patients with chronic kidney disease, those on dialysis, and patients following renal transplantation. This chapter will also discuss the safety, drug dosing, and drug interactions that are important in this group of patients.
17#
發(fā)表于 2025-3-24 14:43:17 | 只看該作者
Dyslipidemia in the Kidney Transplant Patient,recommended. Pharmacological intervention with statin therapy is recommended based on results from the ALERT study, although there is a reluctance to prescribe these agents in transplant recipients due to risk of side effects and drug interactions.
18#
發(fā)表于 2025-3-24 18:35:18 | 只看該作者
https://doi.org/10.1007/978-1-4939-0515-7Dialysis; Dyslipidemias; Geriatric Patient; Hyperlipidemia; Kidney Disease; Lipid Metabolism; Lipid Nephro
19#
發(fā)表于 2025-3-24 21:48:00 | 只看該作者
20#
發(fā)表于 2025-3-25 02:26:49 | 只看該作者
Adrian Covic,Mehmet Kanbay,Edgar V. LermaComprehensive resource that fills a significant knowledge gap.Features the latest clinical evidence and management guidance.Chapters authored by leaders in the field.Includes supplementary material:
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 13:10
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
洱源县| 北流市| 尖扎县| 阜南县| 台东县| 义马市| 夏津县| 石首市| 达日县| 宜川县| 龙川县| 高陵县| 五常市| 安义县| 象州县| 汪清县| 缙云县| 池州市| 冷水江市| 澄城县| 尼木县| 比如县| 乌兰察布市| 灌云县| 如东县| 军事| 阳曲县| 靖西县| 黄山市| 大竹县| 庆阳市| 内江市| 瑞金市| 景德镇市| 延安市| 荔浦县| 禹城市| 来宾市| 抚远县| 上高县| 外汇|